Navigation Links
Radiation and drug combo helps boost efficacy of lung cancer treatment
Date:8/31/2007

DALLAS Sept. 1, 2007 Combining radiation therapy with a drug that helps destroy blood vessels nourishing malignant tumors has been shown in mice to be significantly more effective in treating lung cancer than either approach alone, researchers at UT Southwestern Medical Center have found.

The study, involving human lung-cancer cells implanted in mice, appears in the Sept. 1 issue of Clinical Cancer Research.

In the study, Dr. Philip Thorpe, professor of pharmacology at UT Southwestern, and his colleagues found that radiation generates a chemical reaction in the membranes of endothelial cells, which line the blood vessels that feed tumors. The reaction causes membrane components called anionic phospholipids to flip inside out, exposing them. In normal blood vessels, they face the interior of the cell.

Dr. Thorpes previous research has shown that anionic phospholipids, particularly one called phosphatidylserine, are already flipped inside-out on tumor endothelial cells.

The flipping is likely due to stress conditions present in the tumor micro-environment, and radiation increases the number of exposed phospholipids, said Dr. Thorpe.

Once they induced more flipping with radiation, the researchers administered bavituximab, a monoclonal antibody that homes in on tumor vessels by selectively binding to the inside out phospholipids. The binding signals white blood cells from the immune system to attack and destroy the vessels feeding the tumor.

In their study of mice, the researchers found that radiation increased the percentage of phospholipids that flip inside out from 4 percent to 26 percent. Treating the mice with bavituximab and radiation therapy together reduced tumor growth by 80 percent and was more effective than administering either treatment by itself.

About 30 percent of all lung-cancer patients receive radiation and, in this animal model of lung cancer, we found that this monoclonal anitbody improves the efficacy of radiation therapy without the toxicity seen in other chemotherapeutic drugs, said Dr. Thorpe. Its a win-win.

Bavituximab was created in Dr. Thorpes lab is currently being tested in clinical trials in the U.S. and India for its effectiveness against solid-tumor cancers.

Peregrine Pharmaceuticals Inc. has exclusively licensed bavituximab from UT Southwestern and has a sponsored research agreement to further explore clinical uses of the drug. Dr. Thorpe is a consultant to and has an equity interest in the company.

Lung cancer is the leading cause of cancer death in the U.S. About 213,000 cases of lung cancer will be diagnosed this year and 160,000 people are expected to die from the disease, according to the National Cancer Institute. Although there are current therapies, the five-year survival rate for lung-cancer patients remains at only 15 percent,

Dr. Thorpe said. This tells us that there is an urgent need to develop new treatment strategies. Vascular targeting agents such as bavituximab kill tumors without causing damage to surrounding healthy tissue. They cause fewer side effects than conventional cancer drugs that kill rapidly dividing normal cells along with the cancer cells.

Because Peregrine is already testing bavituximab in cancer patients, Dr. Thorpe said he expects new clinical trials using a combination of bavituximab and radiation therapy to start soon.


'/>"/>

Contact: Connie Piloto
connie.piloto@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Antioxidants protect health tissue in people undergoing radiation therapy.
2. Radiation before surgery cuts cancer recurrence
3. UV Radiation induces Melanoma
4. Low-radiation treatment for brain tumours
5. Lack of solar radiation causes cancer
6. Microwave radiation has no hazards
7. Radiation reduces cancer recurrence
8. Rectal Cancer treated with radiation
9. Radiation before surgery cuts cancer reappearance
10. Ways to counter radiation effects with new molecule discovery
11. Radiation Not Needed for Childhood Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance and Financial ... in Little Rock, has initiated a charity drive to provide support and funding ... End Senior Hunger, Arkansas ranks first in senior hunger statewide, third in child ...
(Date:12/8/2016)... ... 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning firm ... Cape Coral area, is embarking on a charity drive with the goal of providing ... Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious food ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LITTLE FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL ... net income of $18,800,000, or $0.45 per diluted share, on ... the first quarter ended October 31, 2016. This compares with ... sales of $153,779,000 for the first quarter ended October 31, ... the first quarter ended October 31, 2016 to $21,323,000, or ...
(Date:12/8/2016)... , December 8, 2016 Stock-Callers.com ... the research, distribution, and marketing of pharmaceutical drug products. ... patent protection and expiration. Additionally, these firms typically have ... as a whole. Up for review this morning are: ... Pharmaceuticals Inc. (NASDAQ: SGYP ), Pernix Therapeutics ...
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 ... STLT), a pharmaceutical company advancing technologies designed to ... the appointment of Chitra Edwin , Ph.D., ... and Compliance. Dr. Edwin will provide leadership for ... planning for regulatory approvals, preparation of regulatory submissions, ...
Breaking Medicine Technology: